Purpose Accurate risk assessment is necessary for decision-making around breast cancer prevention. We aimed to develop a breast cancer prediction model for postmenopausal women that would take into account their individualized competing risk of non-breast cancer death. Methods We included 73,066 women who completed the 2004 Nurses' Health Study (NHS) questionnaire (all C57 years) and followed participants until May 2014. We considered 17 breast cancer risk factors (health behaviors, demographics, family history, reproductive factors) and 7 risk factors for non-breast cancer death (comorbidities, functional dependency) and mammography use. We used competing risk regression to identify factors independently associated with breast cancer. We validated the final model by examining calibration (expected-to-observed ratio of breast cancer incidence, E/O) and discrimination (c-statistic) using 74,887 subjects from the Women's Health Initiative Extension Study (WHI-ES; all were C55 years and followed for 5 years). Results Within 5 years, 1.8 % of NHS participants were diagnosed with breast cancer (vs. 2.0 % in WHI-ES, p = 0.02), and 6.6 % experienced non-breast cancer death (vs. 
Introduction
Accurate breast cancer risk assessment is necessary to make informed decisions about breast cancer screening and prevention [1, 2] . However, no available breast cancer prediction model considers a woman's individualized risk of non-breast cancer death. Several models (e.g., Breast Cancer Risk Assessment Tool [BCRAT], Tyrer-Cuzick [IBIS] , and Breast Cancer Surveillance Consortium [BCSC] ) factor in a woman's risk of non-breast cancer death based on age alone [3] [4] [5] . As life expectancy varies based on comorbidities and functional status [6] , not accounting for individualized competing risks of nonbreast cancer death risk may lead to inaccurate breast cancer risk estimation among older women.
Statistical methods, such as Fine and Gray's competing risk regression, take into account an individual's risk of non-breast cancer death when estimating breast cancer risk [7] . Conventional methods, such as cause-specific hazard models using Cox proportional hazards regression, focus on the outcome of interest (e.g., breast cancer) and censor women who die from a competing risk before follow-up ends [8] . When death is a common competing event, as it is for elderly women, proportional hazards regression models overestimate risk factor influence on breast cancer incidence since they do not adjust for the reduction in the at risk population due to alternative causes of death [8] [9] [10] . In competing risk regression, women with death from a competing cause are considered no longer at risk for breast cancer. Instead, these women are assigned a weight that is used in the partial likelihood function for breast cancer to account for the time during follow-up that these women were alive before their non-breast cancer death [11] . Experts recommend using competing risk regression for predictive modeling in populations with a high frequency of competing events [12] .
Therefore, we aimed to develop a breast cancer prediction model for postmenopausal women using competing risk regression that would (1) take into account their individualized competing risk of non-breast cancer death, (2) include factors important for estimating postmenopausal breast cancer risk, and (3) use self-reported information for ease of clinical use.
Methods Data
We developed our prediction model using Nurses' Health Study (NHS) data, a longitudinal study of 121,700 female nurses, 30-55 years of age at entry [13] . At baseline and in biennial follow-ups, NHS participants provide detailed lifestyle and medical history information through mailed questionnaires. Our study sample included all NHS participants who returned the 2004 questionnaire. Since this questionnaire could be returned through May 2006, the time of entry into our study varied. We excluded women (n = 9,388) with a history of cancer (except non-melanoma skin cancer) since second diagnoses of cancer are not confirmed. Participants were 57-85 years and postmenopausal at study entry.
Outcomes
We followed participants until they developed invasive breast cancer, died, or May 2014, whichever came first. We included breast cancers confirmed by medical record review and self-reported breast cancers (12 % of cases), since validation studies found that self-reported breast cancers in NHS are accurate (99 % confirmed with medical record review) [14] .
Possible risk factors
We considered four classes of variables in NHS that have been associated with breast cancer in our model, including demographics (age [in 5-year categories for ease of clinical use], race/ethnicity), family history, reproductive factors, and health behaviors [1] . We also considered history of non-traumatic postmenopausal fracture since such fractures may be suggestive of lower estrogen levels [15] . For family history, we considered history of first-degree female relatives with breast cancer and their age at diagnosis (\50 vs C50), history of breast cancer in a grandmother, family history of ovarian cancer, and Ashkenazi Jewish descent. For reproductive factors, we considered age at menarche, menopause, and at first live birth, parity, months breastfeeding, and history of bilateral oophorectomy. Age at menopause for women who underwent simple hysterectomy was derived using a life table approach that incorporated age at surgery, exogenous hormone use, and smoking status. For health behaviors, we considered physical activity, body mass index (BMI), alcohol consumption, cigarette use, postmenopausal hormone therapy use and duration of use (\5, 5? years) for past users, and benign breast biopsy history. While some have found that hormone therapy use modifies the effect of obesity on breast cancer risk, these findings are not consistent, and there were too few current users to consider this interaction [16, 17] . Since weight, alcohol consumption, and physical activity tend to decline with advanced age, we used maximum BMI and maximum average alcohol consumption per day and average physical activity per week reported in the past 10 years. We also considered the influence of mammography use in the past 2 years which increases detection and estimated risk among screened women, and may confound the influence of some risk factors (e.g., family history, breast biopsy history) on breast cancer incidence since these risk factors are associated with increased mammography use [18] .
Factors associated with non-breast cancer death
Competing risk regression assigns a weight to non-breast cancer deaths that is used in the partial likelihood function for assessing breast cancer risk [7] . The assigned weight takes into account the amount of time a participant was in the risk set before experiencing non-breast cancer death, and is a function of factors that are related to both breast cancer incidence and non-breast cancer death (see formula in Appendix). Therefore, we considered additional factors in our model known to be associated with death [6] . Specifically, we considered Charlson comorbidities that were prevalent in [1 % of our cohort and that may be selfreported accurately including diabetes, myocardial infarction (MI), emphysema, congestive heart failure, and stroke [19, 20] . We also considered being limited in moderate daily activities, in bathing oneself, and in walking several blocks (mobility) [21, 22] .
External validation
We examined our model's performance among WHI extension study participants (WHI-ES). We chose to examine our model's performance in a different cohort from the one in which it was developed because we wanted to examine our model's generalizability (external validity). WHI was a multicenter study that recruited 161,808 postmenopausal US women with their ages in the range of 50-79 in up to four clinical trials (WHI-CTs), or an observational study (WHI-OS) from 1993 to 1998, and followed women through March 2005. In 2005, 82 % of WHI-CT participants and 73 % of WHI-OS participants agreed to an observation-only extension study (n = 115,396) through March 2010. 15 In 2010, 86.7 % (n = 79,572) of the 91,800 participants alive agreed to a second extension study through March 2015. We examined our model's performance among WHI-ES participants since the time period matched our NHS cohort and WHI collected the necessary information. WHI-ES participants were 55-91 years at study entry (89 women were 55-56).
We followed WHI-ES participants until they developed invasive breast cancer (all cases confirmed by pathology report), died, the end of WHI-ES1 or the end of WHI-ES2 in 2015 for women who participated in WHI-ES2. To be consistent with NHS, we excluded participants (n = 9778) with history of cancer, except for non-melanoma skin cancers. We also excluded participants missing data on our final model's risk factors (n = 22,229). Detailed descriptions of each cohort and risk factor, and outcome variable definitions are in the Appendix.
Statistical analyses

Model development
We used competing risk regression (CRR) and included all possible breast cancer risk factors. To avoid collinearity, we did not include variables correlated at C0.3 using the Spearman correlation. Women missing risk factor information were included in the model using an indicator variable for missing. We first examined the individual contribution of each breast cancer risk factor on the model's Akaike Information Criterion (AIC) and c-statistic in predicting breast cancer [23] . We kept breast cancer risk factors in the model that improved the AIC and c-statistic, and were statistically significant at p \ 0.05.
In sensitivity analyses, we examined our model's performance stratified by age (55-74 vs. 75? years), and we re-ran our model excluding women missing risk factor information. We also re-ran our analyses using Cox proportional hazards regression (PHR).
External validation
We used Chi square statistics to compare the prevalence of risk factors in each cohort. We then examined model calibration (whether our model's predicted probabilities are accurate) and discrimination (how well our model distinguishes between individuals who do or do not develop breast cancer) [24] . To assess calibration, we compared the expected (E) number of breast cancers at 5 years based on our model's estimates to the observed number (O) in WHI-ES. We examined calibration at 5 years, since we do not have information on whether 8702 WHI-ES participants developed breast cancer after 5 years since they did not consent to WHI-ES2. To determine the expected number of breast cancers among WHI-ES participants at five years, we first obtained the baseline 5-year cumulative incidence function for breast cancer from our NHS model. This allowed us to estimate the baseline breast cancer risk for WHI-ES women without any risk factors. [11] We then multiplied this baseline risk by a WHI-ES woman's individualized hazard ratio for developing breast cancer (calculated based on the presence or absence of risk factors) to estimate breast cancer risk for each WHI-ES participant. Next, we summed these breast cancer risk estimates to obtain the total number of WHI-ES women expected to have breast cancer in 5 years. We repeated these analyses for each risk decile and age group (55-74, 75?). We calculated 95 % confidence intervals (CIs) of E/O ratios using the Poisson variance for the logarithm of the observed number of cases [25] .
To assess discrimination, we used the 5-year breast cancer risk estimates for each WHI-ES participant (calculated as described above), and the observed survival times for WHI-ES participants to compute the c-index (equivalent to c-statistic in logistic regression) and its standard error [26] [27] [28] . This area ranges from 0.5 (no discrimination) to 1.0 (perfect discrimination). In sensitivity analyses, we examined our model's performance by age (55-74, 75? years) and limited WHI-ES to non-Hispanic whites.
To examine if there were differences in the effect of breast cancer risk factors on developing breast cancer between NHS and WHI-ES, we re-ran our model using CRR in WHI-ES. We then compared the effect of each risk factor on developing breast cancer between cohorts using the normal approximation z-test by dividing each risk factor's beta (parameter estimate) by its standard error.
Finally, we demonstrated the practicality of our model by presenting 5-year breast cancer risk predictions for women with different breast cancer risk factors and health characteristics. We also present BCRAT and BCSC risk estimates for these women. All analyses were completed using SAS statistical software, version 9.3 (SAS Institute Inc., NC).
Results
Model development and validation samples
We included 73,066 NHS participants and examined model performance among 74,887 WHI-ES participants (Fig. 1) . Compared with WHI-ES participants, NHS participants were more likely to be non-Hispanic white, nulliparous, to have significant illness, family history of breast cancer, and to have used hormone therapy, but were less likely to have a BMI C30 (kg/m 2 ) or to have been \45 years at menopause (Table 1) . Within 5 years, 1.8 % of NHS participants were diagnosed with breast cancer compared to 2.0 % of WHI-ES participants (p = 0.02), and 6.6 % of NHS participants experienced non-breast cancer death compared to 5.2 % of WHI-ES participants (p \ 0.001).
Model development
We initially considered 17 breast cancer risk factors, recent mammography use, and 6 health conditions in our model ( Table 2 ). History of bilateral oophorectomy and age at menopause were correlated (r = -0.31), and mobility (r = 0.57) and limitations with bathing oneself (r = 0.31) were correlated with being limited in moderate activities and were not included. The c-statistic for this model was 0.62 (95 % CI 0.60-0.63). We kept 8 breast cancer risk factors (the first 8 listed in Table 2 ) in our final model since they improved the model's AIC and c-statistic, and were significant at p \ 0.05. We also kept age group in the model since ages 65-74 were significantly associated with increased breast cancer risk, and age is strongly associated with death. In addition, we kept illnesses and functional limitations in our model since these factors strongly predicted non-breast cancer death (Table 2 ). In addition, we kept mammography use in the model since it was an important predictor of breast cancer among women C75 years (p = 0.05, Table 2 ). The c-statistic of the final 16-variable model (Table 3) using CRR was 0.61 (0.64 among women C75 years, Table 4 ). Excluding women with missing information did not change model performance (Table 3) . Using Cox PHR, the model's c-statistic was 0.61 (0.63 among women C75 years, Table 4 ).Using Cox PHR, the c-statistic of the model in predicting non-breast cancer death was 0.79 (Table 2) .
External validation
Calibration Figure 2 presents the calibration graph and Table 5 reports the E/O ratio and 95 % confidence interval for each risk decile. On average, our model under predicted breast cancer in WHI-ES by 8 % (E/O 0.92 [95 % CI 0.88-0.97], Table 5 ); however, the model tended to predict risk accurately for women at higher risk deciles. Also, stratifying by age, we found that the model accurately 
Comparing risk factors between cohorts
Several risk factors had different effects on developing breast cancer in WHI-ES than in NHS, including age \45 at menopause, being age 25-29 at first birth with C3 children, past cigarette use, current hormone therapy use, diabetes, and having a functional limitation (Table 3 ). The effect of having C2 first-degree relatives (at least one \50 years) also tended to differ between cohorts. Table 6 provides example outputs from our model for women with different breast cancer risk factors and health characteristics. In these examples, we show how accounting for comorbidity and functional limitations leads to lower risk estimates for women, while considering obesity and other behaviors associated with increased breast cancer risk leads to higher risk estimates. Table 6 presents a questionnaire patients could use to complete the model.
Clinical application
Discussion
We developed a novel model for estimating postmenopausal breast cancer risk that considers health behaviors and accounts for individualized competing risks Congestive heart failure, myocardial infarction, and stroke were physician-adjudicated with medical records in WHI-ES f NHS participants were followed through May 2014. All WHI participants were followed through March 2010; 58,534 WHI participants were followed through March 2015 g Other variables that were considered in our NHS model (e.g., age at menarche, months breastfeeding, physical activity, post-menopausal nontraumatic fracture, Ashkenazi Jewish, family history of ovarian cancer, and mobility) but were not included in our final model may be found in Table 1 Breast
of non-breast cancer death. When we examined model performance in WHI-ES, on average, the model accurately predicted breast cancer among women aged 55-74 years but under predicted breast cancer among women C75 years, likely due to greater differences in health characteristics and mammography use in these two age groups. In addition, the model tended to predict risk more accurately for women at higher risk. While model discrimination was modest (c-statistic 0.61), model performance was similar to other commonly used breast cancer prediction models (e.g., BCRAT) [29] . Although we used competing risk regression for model development, using proportional hazards regression led to the same overall c-statistic for the model among women aged 55-74 years, likely because only 3.5 % of women aged 55-74 years experienced non-breast cancer death in 5 years. Among women C75 years, of whom 15 % experienced non-breast cancer death in 5 years, using competing risk regression resulted in a higher c-statistic (c-statistic 0.64) than using Cox PHR (cstatistic 0.63), suggesting using CRR is important when death from competing risks is more common. Our innovative model may be particularly useful for assessing breast cancer risk among postmenopausal women with comorbidity and functional limitations, and in helping postmenopausal women account for their health behaviors when assessing their breast cancer risk. Our model has excellent face validity in that the hazard ratio associated with each risk factor is consistent with Akaike Information Criterion (AIC) is a function of the log-likelihood that adds a penalty of 2 for each additional factor (AIC = -2log-Likelihood ? 2(number of predictors in the model) a Fine and Gray competing risk regression (CRR) allows for estimating the probability of breast cancer conditional on competing risk-free survival. Specifically, CRR assigns a weight less than one to participants who have experienced a competing risk event or are lost to follow-up, and these weights decline with increasing time from the competing event and the event of interest b To improve individualized prediction of mortality, our full model also included significant illnesses (diabetes, myocardial infarction, stroke, emphysema, and congestive heart failure) and functional limitations prior data [1, 30, 31] . The only exception is that past smokers had a non-significant lower risk of breast cancer than non-smokers, possibly because 75 % of NHS participants quit smoking [15 years before the start our study and their past cigarette use may no longer affect their risk [32] . Also, smoking is associated with greater risk of nonbreast cancer death which CRR accounts for in estimating the cumulative incidence of breast cancer. Of note, some factors commonly associated with breast cancer risk were not associated with risk in our model. This could be due to the low prevalence of the risk factor in NHS (e.g., ovarian cancer family history), or that the risk factor is not strongly associated with postmenopausal breast cancer risk (e.g., age at menarche) [1, 30] .
Few prediction models have been tested in populations different from the one in which it was developed, and those that are often perform less well. Our model is no exception. While our model accurately predicted breast cancer among To test whether betas associated with each risk factor differed between cohorts, we used the normal approximation z-test NHS nurses' health study included participants who completed the 2004 questionnaire, WHI-ES women's health initiative extension study which began in 2005-the sample excluded women missing data on variables in our final model a We kept age, comorbidities, and functional limitations in our model because they were significant predictors of death b We kept mammography use in the past two years in the model since it was a significant confounder of breast cancer incidence among women aged 75 and older [33, 34] . Also, WHI-ES participants who had previously participated in the hormone therapy trials were asked to undergo mammography for the first two years of WHI-ES [35] . Possibly as a result, fewer older NHS participants than WHI-ES participants underwent mammography during follow-up (data not shown).
There were other important differences between the WHI-ES and NHS cohorts. WHI-ES is more racially and ethnically diverse than NHS, and although none are currently confirmed, there may be different relationships between model risk factors and breast cancer incidence by race/ethnicity. Also, NHS participants were more likely to die in 5-year follow-up than WHI-ES participants. In addition, WHI-ES participants were less likely to be \45 at menopause, and NHS participants \45 at menopause were much less likely to develop breast cancer than WHI-ES Akaike Information Criterion (AIC) is a function of the log-likelihood that adds a penalty of 2 for each additional factor
Fine and Gray competing risk regression (CRR) allows for estimating the probability of breast cancer conditional on competing risk-free survival. Specifically, CRR assigns a weight less than one to participants who have experienced a competing risk event or are lost to follow-up, and these weights decline with increasing time from the competing event and the event of interest participants \45 at menopause. To participate in WHI's estrogen-alone trial, a prior hysterectomy was required. As women do not uncommonly undergo bilateral oophorectomy along with hysterectomy, a younger average age at menopause for WHI-ES participants could have developed.
In post hoc analyses, we examined the interaction between age of menopause and type of menopause in NHS, but we did not find important interactions (only the missing indicator was significant). Also, WHI-ES uses age 45 rather than age 50 as a cut-off for having a family member diagnosed with breast cancer at a young age which may have led to higher risk estimates for family history of breast cancer among relatives diagnosed at an older age in WHI-ES. Family history of breast cancer was assessed on average eight years before WHI-ES began which may also have led to under-ascertainment in WHI-ES. In addition, similar to other studies, we found that current estrogenalone use was associated with increased breast cancer risk in NHS but not WHI-ES [36, 37] . This finding has been attributed to shorter use of estrogen alone and having started estrogen years past menopause in WHI. In WHI's estrogen-alone trial, the mean age at initiation of estrogen was 64 years and median follow-up was only 7.1 years [36] [37] [38] . Finally, 847 NHS participants (1.2 %) compared to 92 (0.1 %) WHI-ES participants remained alive but did not complete a follow-up questionnaire; breast cancer may have been missed among these women. Our model had similar, modest ability to discriminate which postmenopausal women developed breast cancer as the commonly used BCRAT [39] [40] [41] . Although IBIS has been shown to have better discrimination than BCRAT among women with family history of breast cancer [42] , IBIS's performance has not been tested in a large cohort that includes many women at average risk. Prediction models that include breast density such as BCSC tend to show higher discrimination than BCRAT and our model [5, 43, 44] . However, while the overall c-statistic of the BCSC model was 0.66, its age-adjusted c-statistic was 0.62, and BCSC is not applicable for women [74 years. [5] As an example of how our model may be useful, consider a 63-year-old woman with history of MI and 2 firstdegree relatives with breast cancer. Using BCRAT, her estimated 5-year risk of breast cancer is 5.8 %; with our model that considers her health, it is only 2.3 % (Table 6 ) [26, 27] [2]. Of note, BCSC estimates her risk at 1.3 %, likely because BCSC is known to underestimate risk among women with strong family history of breast cancer [5] . Since our model could be useful to clinicians and postmenopausal women, we plan to make it available on the web and/or as a mobile application [11] . However, first we plan additional analyses. While our model's c-statistic in predicting non-breast cancer death was 0.79, our model was not optimized to predict non-breast cancer death. As a next step, we will incorporate prediction of non-breast cancer death into the model so that women may consider their risk of breast cancer in relation to their risk of nonbreast cancer death when making clinical decisions. This would require us to consider breast cancer death as a competing risk to non-breast cancer death, and we would start the model selection process anew. We also plan to test whether using Surveillance Epidemiology and End Results (SEER) estimates for baseline breast cancer incidence rather than baseline breast cancer incidence rates from NHS improves model performance.
In summary, we developed a novel model that allows users to assess breast cancer risk among postmenopausal women while taking into account their health behaviors and competing risk of non-breast cancer death. Next steps include optimizing the model to predict non-breast cancer death and making the model available for clinical use. Accounting for older women's competing risk of mortality is necessary when assessing their breast cancer risk and making decisions around breast cancer screening and prevention. NY, NC, ND, OH, OK, OR, PA, RI, SC, TN, TX, VA, WA, and WY. In addition, this study was approved by the Connecticut Department of BCRAT breast cancer risk assessment tool [46] , BCSC breast cancer surveillance consortium model [5] a Unless otherwise stated, we assumed a woman had never used hormones, did not have a family history of breast cancer, never had a breast biopsy, never smoked, did not drink alcohol, had a BMI of 20-24 kg/m 2 , was age 20-25 at first birth with 1-2 children, was 14 at age at menarche, had fatty breasts, had a mammogram in the past 2 years, did not have significant illness, and was not limited in moderate daily activities b We do not provide values for a 77-year-old woman using BCSC since the BCSC model does not apply to women [74
